Durability of Antibody Response Against Hepatitis B Virus for a Decreased Crowd: A Retrospective Polycentric Cohort Study from a 10-Year Follow-Up Clinical Study

References

• Qin Y, Liao P. Hepatitis B virus vaccine breakthrough infection: surveillance of S gene mutants of HBV. Acta Virol. 2018;62(2):115–121. doi:10.4149/av_2018_210
   Web of Science ®Google Scholar
• Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol. 2019;25(8):329–334. doi:10.1097/RHU.0000000000000877
   PubMed Web of Science ®Google Scholar
• Seo YB, Moon SJ, Jeon CH, et al. The practice guideline for vaccinating Korean patients with autoimmune inflammatory rheumatic disease. Infect Chemother. 2020;52(2):252–280. doi:10.3947/ic.2020.52.2.252
   Web of Science ®Google Scholar
• Yuan Q, Zhou F, Zhang H, et al. Efficacy and safety of hepatitis B re-vaccination in children after completion of chemotherapy and(or) hematopoietic stem cell transplantation. Zhonghua Er Ke Za Zhi. 2020;58(10):802–806. doi:10.3760/cma.j.cn112140-20200307-00195
   Google Scholar
• Chang SH. Prevention of HBV Recurrence After Liver Transplant: long-Term Results. Transplant Proc. 2021;53(5):1707–1710. doi:10.1016/j.transproceed.2021.04.006
   Web of Science ®Google Scholar
• Urabe A, Imamura M, Tsuge M, et al. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. J Gastroenterol. 2017;52(3):366–375. doi:10.1007/s00535-016-1240-y
   Web of Science ®Google Scholar
• Li AY, Liu Z, Song Y, et al. Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: a large prospective cohort study. Emerg Microbes Infect. 2020;9(1):1881–1891. doi:10.1080/22221751.2020.1808533
   PubMed Web of Science ®Google Scholar
• Xinias I, Vasilaki K, Argiropoulou E, Mavroudi A, Tsiatsiou O, Roilides E. De novo HBV Hepatitis in a Child with Liver Transplantation. Maedica. 2021;16(2):293–296. doi:10.26574/maedica.2020.16.2.293
   Google Scholar
• Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33(2):167–177. doi:10.1055/s-0033-1345722
   PubMed Web of Science ®Google Scholar
• Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol. 2020;14(7):565–578. doi:10.1080/17474124.2020.1774364
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(Suppl):S156–S165. doi:10.1002/hep.22945
   Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;1(370):m2200. doi:10.1136/bmj.m2200
   Web of Science ®Google Scholar
• Lai MW, Lin TY, Liang KH, Lin WR, Yeh CT. Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody. Medicine. 2016;95(49):e5625. doi:10.1097/MD.0000000000005625
   Web of Science ®Google Scholar
• Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon. 2011;11(10):816–820. doi:10.5812/kowsar.1735143X.1771
   PubMed Web of Science ®Google Scholar
• Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. Viruses. 2019;11(11):1049. doi:10.3390/v11111049
   PubMed Web of Science ®Google Scholar
• Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318(5):304–307. doi:10.1016/S0002-9629(15)40643-3
   Web of Science ®Google Scholar
• Chancharoenthana W, Leelahavanichkul A, Udomkarnjananun S, et al. Durability of antibody response against the hepatitis B virus in kidney transplant recipients: a proposed immunization guideline from a 3-year follow-up clinical study. Open Forum Infect Dis. 2018;6(1):ofy342. doi:10.1093/ofid/ofy342
   Web of Science ®Google Scholar
• Rosenau J, Hooman N, Hadem J, et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl. 2007;13(3):367–373. doi:10.1002/lt.21003
   Web of Science ®Google Scholar
• Avakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: a comprehensive review-screened. Hepat Mon. 2016;16(4):e35810. doi:10.5812/hepatmon.35810
   Web of Science ®Google Scholar
• Wang L, Hu H, Zhang R, et al. Changes in the hepatitis B surface antibody in childhood acute lymphocytic leukemia leukemia survivors after treatment with the CCLG-ALL 2008 protocol. Clin Exp Immunol. 2021;203(1):80–86. doi:10.1111/cei.13513
   Web of Science ®Google Scholar
• Hang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative Anti-HBc in liver pathological states in patients with chronic hepatitis B virus infection. Can J Infect Dis Med Microbiol. 2019;2019:6545642. doi:10.1155/2019/6545642
   Web of Science ®Google Scholar
• Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: significance and management. J Clin Med. 2020;9(1):202. doi:10.3390/jcm9010202
   PubMed Web of Science ®Google Scholar
• Drößler L, Lehmann C, Töpelt K, et al. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019;47(2):293–300. doi:10.1007/s15010-019-01271-z
   Web of Science ®Google Scholar
• Yenilmez E, Cetinkaya RA. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: how rational are our prophylaxis decisions according to the literature? Infez Med. 2019;27(3):299–307.
   Google Scholar
• Bazinet M, Anderson M, Pântea V, et al. Analysis of HBsAg immunocomplexes and cccDNA activity during and persisting after nap-based therapy. Hepatol Commun. 2021;5(11):1873–1887. doi:10.1002/hep4.1767
   Web of Science ®Google Scholar
• Kovacic V, Sain M, Vukman V. Efficient hemodialysis hemodialysis improves the response to hepatitis B virus vaccination. Intervirology. 2002;45(3):172–176. doi:10.1159/000065873
   Web of Science ®Google Scholar
• Saberifiroozi M, Gholamzadeh S, Serati AR. The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran. Arch Iran Med. 2006;9(3):204–207.
   Google Scholar
• Lô G, Sow-Sall A, Diop-Ndiaye H, et al. Hepatitis B virus (HBV) infection amongst children in Senegal: current prevalence and seroprotection level. Pan Afr Med J. 2019;25(32):140.
   Google Scholar
• O’Bryan TA, Rini EA, Okulicz J, et al. HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Med. 2015;16(3):161–167. doi:10.1111/hiv.12189
   PubMed Web of Science ®Google Scholar
• Kalchiem-Dekel O, Grupel D, Bouchnik L, Sikuler E, Ben-Yakov G. Efficacy and long-term durability of intradermal recombinant hepatitis B virus vaccine among intramuscular vaccine nonresponders: a prospective study in healthcare personnel. J Gastroenterol Hepatol. 2015;30(12):1782–1787. doi:10.1111/jgh.13022
   Web of Science ®Google Scholar
• Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42–54. doi:10.1016/j.jhep.2022.01.021
   PubMed Web of Science ®Google Scholar
• Xiang D, Ren X, Chen Q, Yu H, Li X, Liu D. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19. Clin Exp Hypertens. 2021;43(4):305–310. doi:10.1080/10641963.2020.1867160
   PubMed Web of Science ®Google Scholar